These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29746209)

  • 1. Improving siRNA Delivery In Vivo Through Lipid Conjugation.
    Osborn MF; Khvorova A
    Nucleic Acid Ther; 2018 Jun; 28(3):128-136. PubMed ID: 29746209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.
    Johannes L; Lucchino M
    Nucleic Acid Ther; 2018 Jun; 28(3):178-193. PubMed ID: 29883296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.
    Sun Y; Zhao Y; Zhao X; Lee RJ; Teng L; Zhou C
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29027965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
    Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
    Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-based nanoparticles in the systemic delivery of siRNA.
    Lin Q; Chen J; Zhang Z; Zheng G
    Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In Vivo.
    Chernikov IV; Meschaninova MI; Chernolovskaya EL
    Methods Mol Biol; 2020; 2115():57-77. PubMed ID: 32006394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges for RNAi in vivo.
    Paroo Z; Corey DR
    Trends Biotechnol; 2004 Aug; 22(8):390-4. PubMed ID: 15283982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery.
    Ma XF; Sun J; Qiu C; Wu YF; Zheng Y; Yu MZ; Pei XW; Wei L; Niu YJ; Pang WH; Yang ZJ; Wang JC; Zhang Q
    J Control Release; 2016 Aug; 235():99-111. PubMed ID: 27242198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
    Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
    Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
    Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
    Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
    Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
    J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.
    Biscans A; Coles A; Echeverria D; Khvorova A
    J Control Release; 2019 May; 302():116-125. PubMed ID: 30940496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
    Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
    J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins.
    Winkler J
    Nucleic Acid Ther; 2018 Jun; 28(3):137-145. PubMed ID: 29733239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-based siRNA Nanodelivery Systems: A Learning Process for Improving Transfer from Concepts to Clinical Applications.
    Pérez SE; Carlucci AM
    Curr Clin Pharmacol; 2018; 13(3):142-163. PubMed ID: 30160217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
    Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
    Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo.
    Hassler MR; Turanov AA; Alterman JF; Haraszti RA; Coles AH; Osborn MF; Echeverria D; Nikan M; Salomon WE; Roux L; Godinho BMDC; Davis SM; Morrissey DV; Zamore PD; Karumanchi SA; Moore MJ; Aronin N; Khvorova A
    Nucleic Acids Res; 2018 Mar; 46(5):2185-2196. PubMed ID: 29432571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.